The crude incidence of treatment-related myelodysplastic syndrome/acute myeloid leukemia has been reported to range from 0 to 12% with conventional dose chemotherapy or radiotherapy, and our 3% is within this range.17 In the long-term update of the LNH-98.5 trial comparing DLBCL treated with CHOP with R-CHOP, 10.8% of patients developed another malignancy since the enrollment.18 Thus, no difference can be acknowledged in the safety profile between R-CHOP alone and R-CHOP followed by RIT. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.